Approval · Notice of Compliance 27991 · 2022
RETEVMO: Notice of Compliance 27991
Issued April 19, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27991
- Date
- April 19, 2022
- Company
- Loxo Oncology Inc
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety update to the Product Monograph Convert the Product Monograph to the 2020 format
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RETEVMO | Not yet assigned | — |
Medicinal ingredients
- SELPERCATINIB 40 MG per CAP
- SELPERCATINIB 80 MG per CAP